Akero Therapeutics, Inc. (AKRO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 19.50 |
| Open | 18.98 |
| Bid | 18.59 x 100 |
| Ask | 18.71 x 100 |
| Day's range | 18.53 - 19.38 |
| 52-week range | 11.25 - 58.38 |
| Volume | |
| Avg. volume | 1,194,568 |
| Market cap | 1.29B |
| Beta (5Y monthly) | -0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
Comprehensive Analysis of Financial Performance and Strategic Progress
- Insider Monkey
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at the Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Steve Cohen and Insiders Are Buying These 5 Stocks. Investors are holding their breath ahead of the key Fed decision about interest rates. While analysts expect the […]
- Zacks
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
© 2024 Yahoo. All rights reserved.